-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[industry trends of pharmaceutical network] recently, the purchase service platform of Guangxi Pharmaceutical Group announced the announcement of negotiation results of purchase (APPROVAL) of Guangxi Pharmaceutical Group by the joint purchase office of Guangxi Pharmaceutical Group Guangxi completed the negotiation of purchase (APPROVAL) of Guangxi Pharmaceutical Group from August 31 to September 1, 2019, and has determined the selected enterprises for each product plan The batch purchase negotiation involves 23 generic names and 63 product specifications, including adefovir dipivoxil, amoxicillin, cefuroxime, lamivudine and other varieties with high purchase amount and large consumption The enterprises to be selected include Zhengda Tianqing, Qilu pharmaceutical, Sinopharm group, Huabei pharmaceutical and other well-known enterprises In fact, Guangxi's notice on the implementation of drug group procurement in the whole region (Draft for comments) has been heard from the industry before, which mentions that the drug group procurement should be implemented in a unified deployment, promotion and implementation in the whole region The medical and health institutions will form Guangxi pharmaceutical purchasing group, and the expert representatives and pharmaceutical manufacturers will conduct bidding, negotiation and other work on the group's pharmaceutical purchasing Guangxi did not disclose the proposed price of the 63 product specifications this time, but according to the price situation of Wuzhou City in Guangxi, the industry believes that Guangxi or Shenzhen price can be referred to, and from the price reduction range of Shanghai and Shenzhen pharmaceutical group purchasing, the price reduction of the 63 product specifications is no less than 30% Among them, Shanghai has long been exploring the implementation of drug group procurement for varieties that have not implemented the volume procurement of medical insurance It is reported that five tertiary hospitals and six districts in Shanghai have formed a Procurement Alliance for public medical institutions Through the alliance's advantages to improve the procurement concentration, optimize the supply chain and other measures, drug prices and procurement costs have been reduced The average price reduction of 42 purchased drugs has reached 60%, with remarkable results Shenzhen GPO (drug group procurement) mode is a third-party centralized agent for public hospitals' procurement demand, group purchase with volume, and direct negotiation with production enterprises Up to now, 14 cities in Guangdong Province have participated in the procurement of Shenzhen Pharmaceutical Group Recently, Shenzhen has made remarkable achievements in drug group procurement According to the calculation of the third-party professional organization, in 2018, Shenzhen GPO saved a total of 1.516 billion yuan in drug procurement costs, with a comprehensive reduction of 21.99% It is reported that the GPO mode in Shenzhen will be promoted to nearly 20 cities at present As of July 15, there are 14 cities that have launched the full drug network platform, and 3 cities in the province that will be launched soon In addition, Wuzhou in Guangxi, Harbin in Heilongjiang, Shihezi in Xinjiang and other regions are also carrying out pilot projects In this context, the drug companies with "gold sales" may gradually withdraw from the market, and the drugs with inflated prices will also tend to be reasonable At present, more than 2000 Medical and health institutions have voluntarily joined Guangxi pharmaceutical purchasing group This time, the number of varieties purchased (batch) by Guangxi Pharmaceutical Group and the actual purchase amount only account for a small part of the number of varieties sold and the actual purchase amount in Guangxi
In the next step, Guangxi will further improve relevant rules and regulations, including expert negotiation rules, transaction settlement, payment and collection mechanism, variety selection rules, procurement, supply and distribution constraint mechanism, and gradually promote the procurement of Guangxi Pharmaceutical Group in accordance with the requirements of unified deployment, promotion and implementation of the whole region, so as to further expand the scope and scope of drug group procurement The amount of drugs purchased by large groups.